Antonio Francesco Di Naro – President & Founder, ADIENNE

11.05.2021
Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how the company’s deal with the Russian Direct Investment Fund happened and some of the challenges related to the manufacturing process. In addition, he highlights the company’s technological expertise and dozens of patents around the world.  
We appeared on [the RDIF's] radar because they were looking for a company with a strong research footprint that could start from the cell all the way to the commercial product
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Switzerland, ADIENNE, Manufacturing, Vaccines

Related Interviews

Barbara Fritsche-Surchat – Managing Director, Servier Switzerland

Barbara Fritsche-Surchat outlines Servier’s historic commitment to Switzerland, how the French mid-cap’s global oncology pivot is translating into its Swiss operations, and comments on the evolution of pharma salesforces post-pandemic.…

Bruno Delie – General Manager, Luye Pharma Switzerland

Luye Pharma is a China-headquartered fully integrated oncology and CNS specialist. Bruno Delie, general manager for Switzerland, discusses the organization’s ambitious European expansion plan, looking to establish affiliates in the…

Karin Blumer – Director Global Patient Engagement, Novartis Oncology

Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being…

Related Articles

Global / Roche to Disentangle from Novartis, Ending Two Decades of Constraints

After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7 billion. While Roche touted…

Long Read / Swiss Biotech - Onwards & Upwards

This piece forms part of InFocus Biotechs to Watch Switzerland 2021, a deep dive into the Swiss biotech ecosystem and fundamentals, featuring data sets, feature articles, and profiles of some…

Europe / Top 5 Countries for Pharma Production

The Top Five countries in Europe for pharma production. All located in Western Europe, Switzerland punches well above its weight to take top spot. This data is taken from the 2021…

Latest Report

Denmark Pharma Report 2021

Related Content

Switzerland
ADIENNE
Manufacturing
Vaccines